Prosecution Insights
Last updated: November 12, 2026
Application No. 18/842,692

SUPER-OXIDE DISMUTASE SOLUBLE FIBER COMPOSITIONS AND METHODS OF USE

Non-Final OA §102§112
Filed
Aug 29, 2024
Priority
Mar 02, 2022 — provisional 63/315,631 +1 more
Examiner
NOAKES, SUZANNE MARIE
Art Unit
1656
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Advance Pharmaceutical Inc.
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
92%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
799 granted / 1087 resolved
+13.5% vs TC avg
Strong +18% interview lift
Without
With
+18.1%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
55 currently pending
Career history
1136
Total Applications
across all art units

Office Action

§102 §112
DETAILED ACTION Notice of AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of Group II, claims 46, 49 and 52 in the reply filed on 17 August 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). The requirement is deemed proper and therefore made Final. Status of Application Claims 1-2, 4, 6-8, 10-11, 14-15, 17, 20, 23, 26-27, 40-41, 46, 49 and 52 are pending; Claims 1-2, 4, 6-8, 10-11, 14-15, 17, 20, 23, 26-27, 40-41 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected subject matter, there being no allowable generic or linking claim. Thus, claims 46, 49 and 52 are subject to examination on the merits. Priority The instant application is a 371 of PCT/US2023/063477 filed 01 March 2023 which claims benefit of US provisional application 63315631 filed 02 March 2022 is acknowledged. Information Disclosure Statement The information disclosure statement (IDS) submitted on 29 August 2024 has been considered by the examiner. See initialed and signed PTO/SB/08. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 46, 49 and 52 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. The claims are drawn to methods of increasing T-cell activation, increasing the production of short chain fatty acids (SCFAs) and increasing the amount of bacteria of the genus Bifidobacterium or Lactobacillus in subjects. However, any asserted improvement in/for anything needs a comparative. That is, increased compared to what (e.g. compared to the levels prior to the administration of the composition)? Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 46, 49 and 52 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Houssain (US 2020/0390867 – cited on IDS). Houssain teaches: Administering Revivify composition, which comprises the following in a gel composition (See Table 1): Revivify Anti - Oxidant Composition 17.88 g/30 ml SI. # Proprietary Blend 17.88 g QTY/mg 1 Soluble corn fiber (Fibersol-2) 4000 2 Pomegranate Juice Concentrate 4000 3 Concord Grape Juice Concentrate 4000 4 Blueberry Juice Concentrate 2000 5 Dark Sweet Cherry Juice Concentrate 1450 6 Sour Cherry Juice Concentrate 1450 7 Goji Pulp 294 8 Acai Concentrate Juice 200 9 Alobira Juice 200 10 Green Tea 200 11 Resveratrol 80 12 Extramel SOD (14000 unit/g) 6 17880 13 CMC 60.5 14 Xanthan 60.5 15 QS Water (30 ml) Thus, the composition comprises 4000mg of soluble corn fiber and 84 U of superoxide dismutase (SOD) (e.g. 14000 Unit/g and the composition comprising 6 mg (.006g) is calculated as: 14000U/g x .006g = 84 Units). Said composition is orally administered to various human patients suffering from a wide-variety of ailments such as: COVID-19, diabetes, Myasthenia Gravis, MS, Gout, Viral symptoms. – See Examples 4-9. Thus, inherently, the patients being administered the liquid gel formulation comprising 4000 mg of soluble corn fiber and 84 U of SOD (among other things) will necessarily have increased T-cell activation, increased SFCA’s and increased Bifidobacterium or Lactobacillus in the digestive track, even if Houssain was not aware of this feature at the time of administering the composition to the different patient/subject populations (MPEP 2112(II)). Thus, the teachings of Hossain inherently anticipate claims 46, 49 and/or 52. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUZANNE M NOAKES whose telephone number is (571)272-2924. The examiner can normally be reached M-F (7-4). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Manjunath Rao can be reached at 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUZANNE M NOAKES/Primary Examiner, Art Unit 1656 21 October 2026
Read full office action

Prosecution Timeline

Aug 29, 2024
Application Filed
Oct 22, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790602
Enzyme Variants and Polynucleotides Encoding Same
8y 0m to grant Granted Nov 10, 2026
Patent 12790617
RECOMBINANT VECTOR COMPRISING HYBRID SIGNAL SEQUENCE, AND SECRETORY PREPARATION METHOD OF HUMAN INSULIN-LIKE GROWTH FACTOR-1 USING THE SAME
3y 11m to grant Granted Nov 10, 2026
Patent 12781160
HOME CARE COMPOSITION
3y 10m to grant Granted Nov 03, 2026
Patent 12781231
METHODS AND MICROORGANISMS FOR MAKING 2,3-BUTANEDIOL AND DERIVATIVES THEREOF FROM C1 CARBONS
2y 8m to grant Granted Nov 03, 2026
Patent 12760297
CRISPR/CAS-CYTIDINE DEAMINASE BASED COMPOSITIONS, SYSTEMS, AND METHODS FOR TARGETED NUCLEIC ACID EDITING
6y 10m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
92%
With Interview (+18.1%)
Low
PTA Risk
Based on 1087 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month